By Tom Winnifrith, The Sheriff of AIM | Thursday 9 March 2017
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
I am beginning to think that the 32p I invested in buying one share in Advanced Oncotherapy (AVO) may be dead money sooner than I think. The silence on certain matters relating to the £11 million it owes Metric is deafening and leads me to believe that on March 31 this company could be insolvent. Or is it already insolvent? The first question is whether Advanced has breached covenants on the loan already and so is in technical default, i.e. insolvent. If that is the case investors should be told at once should they not. Perhaps hapless Nomad Stockdale might force a clarification of this matter?
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |